The record
| Class | nootropic |
|---|---|
| Also known as | N-Acetyl Selank, Ac-Selank, Acetylated Selank |
| Chain length | - |
| Molecular weight | 793.92 Da |
| Half-life | 2-4 hours (enhanced vs regular Selank) |
| Route | IN (intranasal) / SC |
| Studied for | Anxiety disorders; Depression (adjunct); Cognitive enhancement; Stress reduction |
| Research use | Anxiolytic mechanism studies; Neuropeptide research; BDNF modulation |
| What has been shown | Reduced anxiety without sedation; Improved memory and learning; Enhanced stress resilience; Modulates immune responses |
| How it works | N-acetylated version of Selank with enhanced stability and potentially different receptor binding. Anxiolytic heptapeptide derived from tuftsin with added Pro-Gly-Pro stabilizing sequence. Modulates BDNF, enkephalins, serotonin, dopamine, and norepinephrine. Affects GABA system without benzodiazepine-like sedation. Enhances IL-6 in depression models. N-acetylation may alter BBB penetration and rec |
| Patent status | various formulation patents |
| Regulatory status | research only |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Stress Modulation / Calm State (affection, 100%)
- Mood Stability Environment (affection, 73%)
- adaptation disorders (illness, 45%)
- Anxiety disorders (illness, 100%)
- anxiety disorders / anxiety states (illness, 45%)
- astheno-neurotic states (illness, 45%)
- Cognitive enhancement (illness, 100%)
- Depression (illness, 100%)
- Incomplete abortion (illness, 40%)
- Labor augmentation (illness, 40%)
- Labor induction (illness, 40%)
- Postpartum hemorrhage prevention/treatment (illness, 40%)
- Stress reduction (illness, 100%)
- Poor sleep (symptom, 33%)
- Anxiety or stress (symptom, 100%)
- Low mood (symptom, 67%)